Medical Prognosis Institute/Oncology Venture
Medical Prognosis Institute (MPI), Oncology Venture (OV) & 2X-Oncology Inc.
We match patients and drugs.
MPI develops Precision Medicine via our mRNA Drug Response Predictor-DRP™, a unique companion diagnostic tool.
OV - a spinout MPI - uses the DRP(TM) to select high likelihood responding patients for its pipeline of 7 focused Phase 2 anti cancer drugs. Three of these drugs are developed in 2X-Oncology Inc. a Precision Medicine company for Woman’s Cancer & spin out of OV.